Freeline Therapeutics Holdings Plc  (FRLN)
Other Ticker:  
Price: $6.4800 $0.00 0.000%
Day's High: $6.49 Week Perf: 0.47 %
Day's Low: $ 6.48 30 Day Perf: 1.73 %
Volume (M): 6 52 Wk High: $ 8.70
Volume (M$): $ 36 52 Wk Avg: $4.29
Open: $6.49 52 Wk Low: $0.23

 Market Capitalization (Millions $) 384
 Shares Outstanding (Millions) 59
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -89
 Cash Flow (TTM) (Millions $) -70
 Capital Exp. (TTM) (Millions $) 7

Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc is a gene therapy company focusing on developing unique treatments for patients suffering from genetic diseases. They use a proprietary technology platform to design, construct, and deliver gene therapies directly to target cells within the body. Freeline's mission is to provide one-time transformative treatments that can potentially cure or significantly improve the lives of patients with genetic disorders. The company is headquartered in the United Kingdom and is publicly traded on the London Stock Exchange under the ticker symbol FRLN.

   Company Address: Sycamore House Stevenage 0
   Company Phone Number: (0)1438 906870   Stock Exchange / Ticker: NASDAQ FRLN


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Windtree Therapeutics Inc

Among many companies, the WINT published as well its fourth quarter of 2023 results

The investors have not anticipated some adjustments at the revenue throughout the the earnings season of the October to December 31 2023 at the Windtree Therapeutics Inc. However, they observe the Biotechnology and Pharmaceuticals company's operating deficit that was at $-4.959 million, during the same period.

Ocugen Inc

The Biotechnology and Pharmaceuticals company reported Revenue of $6.036 million, in the most recent fiscal period

OCGN has seen $6.036 million, in Revenue in the fourth quarter of 2023 earnings season.

Nkgen Biotech Inc

the Biotechnology and Pharmaceuticals company over the financial fourth quarter of 2023

In its most recent fiscal period Nkgen Biotech Inc increased a shortfall per share at $-4.82 per share, opposite of $-0.14 per share a year prior financial reporting period, In the preceding financial reporting period NKGN realized $-2.48 per share.

Qrons Inc

The Biotechnology and Pharmaceuticals company created some good scenario for the shareholders, exhibiting a relevant rise in October to December 31 2023 with operating shortfall of $-0.143762 million

After the big players in the Biotechnology and Pharmaceuticals sector, a few lesser known entities are impending with the results. Qrons Inc said it has clinched operating shortfall of $-0.143762 million, for the fourth quarter of 2023.

Mosaic Immunoengineering Inc

Mosaic Immunoengineering Inc declared operating loss in the fourth quarter of 2023

Trailing the big players in the Biotechnology and Pharmaceuticals industry, a number of smaller companies are reporting their earnings. PTSC said it has announced operating loss of $-0.275618 million, for the fourth quarter of 2023.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com